145 related articles for article (PubMed ID: 37589934)
41. BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc.
Li N; Yang L; Qi XK; Lin YX; Xie X; He GP; Feng QS; Liu LR; Xie X; Zeng YX; Feng L
Cell Death Dis; 2018 Jul; 9(7):761. PubMed ID: 29988031
[TBL] [Abstract][Full Text] [Related]
42. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
43. Enzyme-responsive micellar JQ1 induces enhanced BET protein inhibition and immunotherapy of malignant tumors.
Zhang Z; Zhang Q; Xie J; Zhong Z; Deng C
Biomater Sci; 2021 Oct; 9(20):6915-6926. PubMed ID: 34524279
[TBL] [Abstract][Full Text] [Related]
44. Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer.
Pérez-Peña J; Győrffy B; Amir E; Pandiella A; Ocaña A
Breast Cancer Res Treat; 2018 Dec; 172(3):725-732. PubMed ID: 30206781
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological Targeting of BET Bromodomains Inhibits Lens Fibrosis via Downregulation of MYC Expression.
Wang X; Wang B; Zhao N; Wang C; Huang M; Chen B; Chen J; Sun Y; Xiong L; Huang S; Liu Y
Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4748-4758. PubMed ID: 31731295
[TBL] [Abstract][Full Text] [Related]
46. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Liu X; Wu H; Huang P; Zhang F
J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
[TBL] [Abstract][Full Text] [Related]
47. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
[TBL] [Abstract][Full Text] [Related]
48. Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation.
Fourniols T; Maggio V; Rafael D; Colaco A; Vidal EG; Lopes A; Schwartz S; Martínez-Barriocanal Á; Preat V; Arango D
Eur J Pharm Biopharm; 2022 Feb; 171():39-49. PubMed ID: 34998911
[TBL] [Abstract][Full Text] [Related]
49. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer.
Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H
J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869
[TBL] [Abstract][Full Text] [Related]
50. Conditioned medium from stimulated macrophages inhibits growth but induces an inflammatory phenotype in breast cancer cells.
Song W; Thakor P; Vesey DA; Gobe GC; Morais C
Biomed Pharmacother; 2018 Oct; 106():247-254. PubMed ID: 29966967
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
52. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
53. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.
Bonazzoli E; Predolini F; Cocco E; Bellone S; Altwerger G; Menderes G; Zammataro L; Bianchi A; Pettinella F; Riccio F; Han C; Yadav G; Lopez S; Manzano A; Manara P; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Schlessinger J; Santin AD
Clin Cancer Res; 2018 Oct; 24(19):4845-4853. PubMed ID: 29941483
[No Abstract] [Full Text] [Related]
55. BET-directed PROTACs in triple negative breast cancer cell lines MDA-MB-231 and MDA-MB-436.
Teufelsbauer M; Stickler S; Eggerstorfer MT; Hammond DC; Hamilton G
Breast Cancer Res Treat; 2024 Jun; ():. PubMed ID: 38896334
[TBL] [Abstract][Full Text] [Related]
56. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines.
Özgür A; Kara A; Gökşen Tosun N; Tekin Ş; Gökçe İ
Mol Biol Rep; 2021 Apr; 48(4):3439-3449. PubMed ID: 33999319
[TBL] [Abstract][Full Text] [Related]
57. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
58. Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma.
Lee DH; Qi J; Bradner JE; Said JW; Doan NB; Forscher C; Yang H; Koeffler HP
Int J Cancer; 2015 May; 136(9):2055-64. PubMed ID: 25307878
[TBL] [Abstract][Full Text] [Related]
59. Toxicity of JQ1 in neuronal derivatives of human umbilical cord mesenchymal stem cells.
Bakshi S; McKee C; Walker K; Brown C; Chaudhry GR
Oncotarget; 2018 Sep; 9(73):33853-33864. PubMed ID: 30333915
[TBL] [Abstract][Full Text] [Related]
60. Senescence-associated IL-6 and IL-8 cytokines induce a self- and cross-reinforced senescence/inflammatory milieu strengthening tumorigenic capabilities in the MCF-7 breast cancer cell line.
Ortiz-Montero P; Londoño-Vallejo A; Vernot JP
Cell Commun Signal; 2017 May; 15(1):17. PubMed ID: 28472950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
